Tempus AI, Inc.
Chicago, IL Doing business as Tempus Labs Inc.
- UEI
- PW4TQZ3KDLU3
- CAGE
- 7WPH7
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- Corporate family
-
-
Tempus AI, Inc.
PW4TQZ3KDLU3
- Ambry Genetics Corporation E1VBXEM76NC5
-
Tempus AI, Inc.
PW4TQZ3KDLU3
- SAM.gov registration date
- Physical address
- 600 W Chicago Ave #510, Chicago, IL 60654, USA
- Website
- tempus.com
- Founded
- 2015
- Employees
- 1K-5K
- Estimated annual revenue
- $500M-$1B
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Tasso+ assay testing for MVP program | Veterans Integrated Service Network 4 | $2,500,850 | |
| Tasso+ assay testing for MVP program | Veterans Integrated Service Network 4 | $8,394,876 | |
| Tasso+ sequencing for MVP program | Veterans Integrated Service Network 4 | $2,695,907 | |
| Modification P9 to change the contracting officer and add vaar clause 852.222-71 compliance with executive order 13899 | Headquarters | $5,525,284 | |
| Adapt CRO support services solicitation | National Institutes of Health | $24,192,040 |
About Tempus AI, Inc.
Tempus AI, Inc. (doing business as Tempus Labs Inc.) delivers precision medicine and advanced genomic sequencing services to federal healthcare and research agencies as a prime contractor, with no subcontract footprint and no set-aside designations across its federal portfolio. The Chicago-based for-profit corporation specializes in tumor-normal matched genomic testing, comprehensive genomic profiling, DNA methylation analysis, and genome-wide association studies to support oncology-related patient care and precision medicine research across the Department of Veterans Affairs and the National Institutes of Health. Tempus holds a named subsidiary, Ambry Genetics Corporation, a for-profit organization.
Tempus's customer base concentrates heavily on the VA system. The Department of Veterans Affairs accounts for 93% of recent awards by count and $137.9 million in combined potential value across two distinct contract vehicles, while the NIH contributes the second-largest dollar value at $59.2 million from a single definitive contract. Within VA, the Headquarters office and Veterans Integrated Service Network 1 (Million Veteran Program) dominate, with the former holding 7 awards ($91.8 million) and the latter holding 3 awards ($46.3 million). A small volume of work flows through Veterans Integrated Service Network 7 ($67 thousand). The portfolio spans 15 total awards across 6 customer agencies, with 27% of combined potential value obligated to date.
Tempus operates through two primary vehicle positions. The older $64.3 million single-award Indefinite Delivery Contract (36C10G22D0004) with VA Headquarters, awarded January 28, 2022, and running through January 27, 2027, has generated 6 delivery orders valued at $27.5 million combined, with individual task orders ranging from $293 thousand to $7.99 million. A newer $35.2 million single-award IDIQ (36C24E26D0008) awarded March 2, 2026, to Veterans Integrated Service Network 1 for TASSO+ assay testing supporting the Million Veteran Program extends through March 1, 2031, and has issued 2 delivery orders to date ($11.1 million combined). Representative delivery orders include an $8.39 million firm fixed-price order for TASSO+ assay testing awarded July 1, 2026, and a $59.2 million Time and Materials definitive contract with the NIH awarded September 18, 2025, for ADAPT CRO Support Services through September 17, 2030. All work carries full-and-open competitive designation with no set-aside applied.
Activity has grown from one award in 2023 to four in 2026 year-to-date. Five awards (combined potential value $28.3 million) expire within the next twenty-four months, creating recompete exposure on the original VA IDC and related delivery orders as the January 27, 2027, ultimate completion date approaches. Work is performed across Tempus facilities in Chicago, Illinois and Fredericksburg, Virginia, with DC-area support for the NIH engagement. The VA accounts for most delivery-order volume under its core genomic testing vehicle, while the newer MVP-focused IDIQ signals expansion into specialized assay testing (TASSO+ platform) for large-scale genomic research initiatives.
Quick answers
What is Tempus AI, Inc.'s UEI?
Tempus AI, Inc.'s Unique Entity ID (UEI) in SAM.gov is PW4TQZ3KDLU3.
What is Tempus AI, Inc.'s CAGE code?
Tempus AI, Inc.'s CAGE code is 7WPH7.
What is Tempus AI, Inc.'s primary NAICS code?
Tempus AI, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Tempus AI, Inc. located?
Tempus AI, Inc.'s physical address in SAM.gov is 600 W Chicago Ave #510, Chicago, IL 60654, USA.
Is Tempus AI, Inc. registered in SAM.gov?
Yes. Tempus AI, Inc.'s SAM.gov registration is active through August 18, 2027.
What is Tempus AI, Inc.'s most recent federal award?
Tempus AI, Inc.'s most recent federal contract award is Tasso+ assay testing for MVP program (36C24E26N0239), from Veterans Integrated Service Network 4, on September 15, 2026.
On GovTribe
See Tempus AI, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors